Pharmaceuticals, Biotechnology & Life Sciences

Insider buying by AstraZeneca SVP Sharma Mani boosts confidence in the drugmaker’s oncology pipeline and $1 billion capital plan.

Neurocrine CMO Roberts Eiry’s 51k‑share stake signals deep insider confidence—insight on options, RSUs, and what it means for investors and the company’s future.

Insight into Charles River Laboratories insider trades: how CEO Parisotto’s buy‑sell strategy signals confidence and risk‑aware growth.

Sell‑to‑cover trades at Bicycle Therapeutics reveal routine tax‑planning, not a signal of weakness—insiders remain confident while the stock steadies near $3.79.

Neurocrine insider trades reveal exec confidence and disciplined liquidity—stable equity holdings, robust R&D and a mid‑cap biotech outlook.

Inside Recursion’s recent insider sales, learn why the moves signal planned liquidity—not panic—and how the AI‑drug platform still drives upside potential.

CEO Ranee GALA’s 2,000‑share sale is a routine 10‑b‑5‑1 move, showing confidence in Jazz Pharma’s strong pipeline and steady upside.

Mark Boulding’s latest PTC Therapeutics buy shows insider confidence and may signal a short‑term uptick, but investors should weigh the firm’s valuation risks.

Coen Steven P. sells 2,403 Ginkgo Bioworks shares at $15, signaling steady insider confidence while the company scales its synthetic‑biology platform and eyes new funding rounds.

Illumina CEO Thaysen Jacob sells 1,303 shares—minor portfolio tweak, not a red flag. Understand why insiders trade and focus on Illumina’s strong growth.